File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intensive chemotherapy for peripheral T-cell lymphomas

TitleIntensive chemotherapy for peripheral T-cell lymphomas
Authors
KeywordsNon‐Hodgkin's lymphoma
T‐immunophenotype
Issue Date1992
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1992, v. 10 n. 3-4, p. 155-161 How to Cite?
AbstractForty-two patients with previously untreated peripheral T-cell lymphomas (PTCL) were treated with an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. Patients achieving complete clinical remission after three courses were given intensive consolidation and maintenance chemotherapy similar to the L10/L17M protocol designed by the Memorial Sloan-Kettering Group for acute lymphoblastic leukemia and lymphoblastic lymphoma. There were 27 (64 per cent) males and 15 (36 per cent) females. The median age was 54 years (mean 53, range 15 to 68). Seven of them (17 per cent) had stage I disease, four (10 per cent) stage II, seven (17 per cent) stage III and 24 (57 per cent) stage IV. Eighteen patients (43 per cent) had B symptoms and four (10 per cent) had bulky disease. According to the Working Formulation, the histology was diffuse mixed in 16 patients (38 per cent), diffuse large cell in 18 (43 per cent), diffuse immunoblastic in four (10 per cent) and unclassifiable in four (10 per cent). According to a modified Japanese Lymphoma Study Group's classification, the histology in 24 patients (57 per cent) was the pleomorphic type, in 13 (31 per cent) immunoblastic-lymphadenopathy-like (IBL-like), and in five (12 per cent) unclassifiable. The overall complete remission rate was 67 per cent. Twenty-five per cent of the complete responders relapsed and the DFS of the CR patients was 62 per cent at three years. The overall survival of all patients at three years was 52 per cent. Patients with stage I, II and III disease had significantly better CR rate (100 per cent versus 42 per cent, p = 0.001) and overall survival (82 per cent versus 35 per cent at three years, p = 0.01) than those with stage IV disease but the relapse rate and DFS of CR patients were similar. This study shows that the prognosis of patients with PTCL can be improved by intensive therapy.
Persistent Identifierhttp://hdl.handle.net/10722/161942
ISSN
2023 Impact Factor: 3.3
2023 SCImago Journal Rankings: 0.820
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorChiu, Een_US
dc.contributor.authorLie, Aen_US
dc.contributor.authorHo, FCSen_US
dc.contributor.authorLoke, SLen_US
dc.date.accessioned2012-09-05T05:16:12Z-
dc.date.available2012-09-05T05:16:12Z-
dc.date.issued1992en_US
dc.identifier.citationHematological Oncology, 1992, v. 10 n. 3-4, p. 155-161en_US
dc.identifier.issn0278-0232en_US
dc.identifier.urihttp://hdl.handle.net/10722/161942-
dc.description.abstractForty-two patients with previously untreated peripheral T-cell lymphomas (PTCL) were treated with an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. Patients achieving complete clinical remission after three courses were given intensive consolidation and maintenance chemotherapy similar to the L10/L17M protocol designed by the Memorial Sloan-Kettering Group for acute lymphoblastic leukemia and lymphoblastic lymphoma. There were 27 (64 per cent) males and 15 (36 per cent) females. The median age was 54 years (mean 53, range 15 to 68). Seven of them (17 per cent) had stage I disease, four (10 per cent) stage II, seven (17 per cent) stage III and 24 (57 per cent) stage IV. Eighteen patients (43 per cent) had B symptoms and four (10 per cent) had bulky disease. According to the Working Formulation, the histology was diffuse mixed in 16 patients (38 per cent), diffuse large cell in 18 (43 per cent), diffuse immunoblastic in four (10 per cent) and unclassifiable in four (10 per cent). According to a modified Japanese Lymphoma Study Group's classification, the histology in 24 patients (57 per cent) was the pleomorphic type, in 13 (31 per cent) immunoblastic-lymphadenopathy-like (IBL-like), and in five (12 per cent) unclassifiable. The overall complete remission rate was 67 per cent. Twenty-five per cent of the complete responders relapsed and the DFS of the CR patients was 62 per cent at three years. The overall survival of all patients at three years was 52 per cent. Patients with stage I, II and III disease had significantly better CR rate (100 per cent versus 42 per cent, p = 0.001) and overall survival (82 per cent versus 35 per cent at three years, p = 0.01) than those with stage IV disease but the relapse rate and DFS of CR patients were similar. This study shows that the prognosis of patients with PTCL can be improved by intensive therapy.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_US
dc.relation.ispartofHematological Oncologyen_US
dc.subjectNon‐Hodgkin's lymphoma-
dc.subjectT‐immunophenotype-
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshBleomycin - Administration & Dosageen_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshDexamethasone - Administration & Dosageen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunophenotypingen_US
dc.subject.meshLeucovorin - Administration & Dosageen_US
dc.subject.meshLymphoma, T-Cell, Peripheral - Classification - Drug Therapy - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMethotrexate - Administration & Dosageen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrednisone - Administration & Dosageen_US
dc.subject.meshPrognosisen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titleIntensive chemotherapy for peripheral T-cell lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hon.2900100305en_US
dc.identifier.pmid1383118-
dc.identifier.scopuseid_2-s2.0-0026709884en_US
dc.identifier.volume10en_US
dc.identifier.issue3-4en_US
dc.identifier.spage155en_US
dc.identifier.epage161en_US
dc.identifier.isiWOS:A1992JU20700004-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridChiu, E=24827833600en_US
dc.identifier.scopusauthoridLie, A=24284842400en_US
dc.identifier.scopusauthoridHo, FCS=7103408147en_US
dc.identifier.scopusauthoridLoke, SL=7006559512en_US
dc.identifier.issnl0278-0232-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats